Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
March 08, 2024 16:02 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology
March 07, 2024 16:01 ET
|
Akero Therapeutics Inc.
As reported previously, the addition of EFX to GLP-1 receptor agonist therapy had a safety and tolerability profile comparable to that of EFX alone and led to statistically significant improvements in...
Akero Therapeutics Announces Pricing of Public Offering of Common Stock
March 05, 2024 21:13 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces Proposed Public Offering of Common Stock
March 04, 2024 16:21 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
March 04, 2024 06:00 ET
|
Akero Therapeutics Inc.
50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%) 50mg...
Akero Therapeutics to Present Topline Week 96 Results from Phase 2b HARMONY Study Investigating Efruxifermin in Patients with Pre-Cirrhotic MASH
February 29, 2024 08:00 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024 07:00 ET
|
Akero Therapeutics Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024 08:15 ET
|
Akero Therapeutics
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious...
Akero Therapeutics Announces First Patients Dosed in Efruxifermin Phase 3 SYNCHRONY Program
December 18, 2023 07:00 ET
|
Akero Therapeutics
Week 96 Phase 2b HARMONY Results for Treatment of Patients with Pre-Cirrhotic NASH/MASH (F2-F3) to be Reported in March 2024 End-of-Phase 2 FDA Meeting Scheduled for the first quarter of 2024 to...
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 07:00 ET
|
Akero Therapeutics
-- Phase 3 SYNCHRONY studies actively screening and on track to begin enrolling by the end of 2023 -- SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Akero...